NCT07046780尚未招募不适用
A Multicenter, Prospective, Non-Interventional Real-World Study of Iparomlimab and Tuvonralimab Injection (QL1706) in the Treatment of Locally Advanced or Metastatic Solid Tumors
PENG YUAN1 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2025年7月30日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 90
- 试验地点
- 1
- 主要终点
- Incidence of Grade ≥3 irAEs
研究概览
简要总结
This study is a prospective, observational, real-world, multi-center study planning to enroll 90 patients. The study will observe and document patients' actual clinical practices in receiving Iparomlimab and Tuvonralimab Injection (QL1706). The primary objectives are to evaluate the safety and effectiveness of Iparomlimab and Tuvonralimab Injection (QL1706) in treating locally advanced or metastatic solid tumors.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed locally advanced or metastatic solid tumors with disease progression (radiographic or clinical) after ≥1 line of prior standard therapy, unsuitable for/intolerant to standard therapy. Includes but not limited to: Gastrointestinal tumors (colorectal cancer, hepatocellular carcinoma, esophageal cancer, biliary tract cancer, pancreatic cancer, gastric cancer), Breast cancer, Non-small cell lung cancer (NSCLC), Small cell lung cancer (SCLC), Soft tissue sarcoma;
- •ECOG performance status 0-2;
- •≥1 measurable lesion per RECIST v1.1 ;
- •Adequate organ function meeting ALL criteria below:
- •Hematology (without transfusion/G-CSF support within 7 days):
- •Absolute neutrophil count (ANC) ≥1.5×10⁹/L Platelets ≥100×10⁹/L Hemoglobin ≥90 g/L
- •Biochemistry :
- •Total bilirubin (TBIL) ≤2×ULN ALT/AST ≤2.5×ULN (≤5×ULN if liver metastases present) Serum creatinine (Cr) ≤1.5×ULN Albumin ≥28 g/L
- •Urinalysis :
- •Urine protein <2+ (dipstick) If protein ≥2+, 24h urinary protein ≤1.0 g
- •Coagulation (without anticoagulants):
- •PT/APTT/INR ≤1.5×ULN
- •Life expectancy ≥12 weeks;
- •Contraception : Females of childbearing potential or males with partners of childbearing potential must use effective contraception during treatment and for 6 months post-treatment;
- •Signed informed consent and protocol compliance.
排除标准
- •Tumor-Related Conditions
- •Known CNS metastases (except those radiologically stable ≥4 weeks after radiotherapy);
- •Other malignancies within past 5 years, excluding:
- •Cured basal/squamous cell skin cancer Localized low-risk prostate cancer Cervical/breast carcinoma in situ
- •Severe bone lesions from metastatic disease, including:
- •Uncontrolled bone pain Pathologic fractures at critical sites (within 6 months) or impending spinal cord compression;
- •Uncontrolled effusions requiring recurrent drainage (pleural/pericardial/ascites), per investigator assessment.
- •Prior Anti-tumor Therapy
- •Prior systemic therapy with CTLA-4 inhibitors or other ICIs;
- •Any anti-tumor treatment within 4 weeks before first dose, including:
- •Surgery/chemotherapy/palliative radiotherapy to non-target lesions/hormonal/targeted/biologic/immunotherapy;
- •Treatment-related toxicities not recovered to CTCAE grade ≤1 (exceptions: alopecia/platinum-induced neuropathy ≤ grade 2).
- •Comorbidities & History
- •Arterial thromboembolism within 6 months (MI/unstable angina/stroke/TIA);
- •Symptomatic heart failure (NYHA class III-IV), unstable angina, or uncontrolled arrhythmia;
- •Severe pulmonary disease : ILD/COPD/symptomatic bronchospasm;
- •Active uncontrolled infection (≥CTCAE grade 2), including:
- •HIV Active HBV (DNA ≥500 IU/mL) HCV (Ab+ with detectable RNA) HBV/HCV co-infection;
- •History of neurologic/psychiatric disorders;
- •Recent or current substance abuse;
- •Prior allogeneic organ/hematopoietic stem cell transplantation.
- •Hypersensitivity to study drug or its excipients.
- •Active autoimmune disease requiring treatment or history within 2 years. Exceptions: Vitiligo/alopecia/psoriasis not needing systemic therapy Hypothyroidism managed only with hormone replacement Type 1 diabetes controlled solely with insulin.
- •Pregnant/lactating women;
- •Any uncontrolled systemic disease increasing study risk (per investigator);
- •Other unsuitable conditions determined by investigator.
研究组 & 干预措施
Observation group
Patients treated with Iparomilimab and Tuvonralimab in the real world
干预措施: Observation arm (Drug)
结局指标
主要结局
Incidence of Grade ≥3 irAEs
时间窗: 2 years
次要结局
- Incidence of immune-related adverse events(2 years)
- Incidence of treatment-related adverse events(2 years)
- Incidence of adverse events(2 years)
研究者
PENG YUAN
Professor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Registry Study in MSI/dMMR Solid TumorsDMMR CancerSolid TumorMSI-HNCT06004713Peking University Cancer Hospital & Institute190
已完成
不适用
A Real-world Study to Assess Safety and Effectiveness of Secukinumab in Pediatric Plaque Psoriasis Patients in ChinaModerate to Severe Chronic Plaque PsoriasisNCT05388916Novartis Pharmaceuticals42
招募中
不适用
The Impact of Immune Cell Changes During the Perioperative Period on the Prognosis of Patients With Colorectal CancerColorectal CancerNCT05015296Beijing Friendship Hospital7,000
已完成
不适用
A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in ChinaPsoriasisNCT04894890Novartis Pharmaceuticals1,002
已完成
不适用
Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese PatientsProstate CancerOvarian CancerNCT04560452AstraZeneca1,018